Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

RHEUMATOID ARTHRITIS

Testing the anti-osteoclastic function of biologic DMARDs

Nature Reviews Rheumatology volume 14, pages 446–448 (2018)Cite this article

Subjects

A variety of biologic DMARDs now exist for the treatment of rheumatoid arthritis, but we don’t really know how these drugs function in vivo. Can time-lapse intravital imaging distinguish the modes of action of DMARDs by comparing response to joint destruction in mouse models of arthritis?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Biologic DMARD mechanisms.

References

  1. Shim, J. H., Stavre, Z. & Gravallese, E. M. Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif. Tissue Int. 102, 533–546 (2018).

    Article  PubMed  CAS  Google Scholar 

  2. Burmester, G. R. et al. Managing rheumatic and musculoskeletal diseases — past, present and future. Nat. Rev. Rheumatol. 13, 443–448 (2017).

    Article  PubMed  CAS  Google Scholar 

  3. Matsuura, Y. et al. In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212880 (2018).

    Article  PubMed  Google Scholar 

  4. Dimitroulas, T. et al. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun. Rev. 12, 958–966 (2013).

    Article  PubMed  CAS  Google Scholar 

  5. Robling, A. D. & Stout, S. D. Morphology of the drifting osteon. Cells Tissues Organs 164, 192–204 (1999).

    Article  PubMed  CAS  Google Scholar 

  6. Kliwinski, C. et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J. Autoimmun. 25, 165–171 (2005).

    Article  PubMed  CAS  Google Scholar 

  7. Kikuta, J. et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J. Clin. Invest. 123, 866–873 (2013).

    PubMed  PubMed Central  CAS  Google Scholar 

  8. Axmann, R. et al. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67, 1603–1609 (2008).

    Article  PubMed  CAS  Google Scholar 

  9. Schett, G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 9, 203 (2007).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Cutolo, M. et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res. Ther. 11, R176 (2009).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank S. Paolino, S. Soldano, R. Brizzolara and staff members at the Research Laboratory and Division of Clinical Rheumatology of the University of Genova for their support in the compilation of the manuscript.

Author information

Authors and Affiliations

  1. Research Laboratories and Academic Division of Rheumatology, Postgraduate School of Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genova, Italy

    Maurizio Cutolo & Alberto Sulli

Authors
  1. Maurizio Cutolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Sulli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio Cutolo.

Ethics declarations

Competing interests

M.C. declares he has received university research funds from Actelion Pharmaceuticals Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, and Horizon Pharma. A.S. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cutolo, M., Sulli, A. Testing the anti-osteoclastic function of biologic DMARDs. Nat Rev Rheumatol 14, 446–448 (2018). https://doi.org/10.1038/s41584-018-0046-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-018-0046-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing